Company: LGNZZ
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000886163-25-000051
Chunk: 5

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-08-08
Form: 10-Q
Item: Item 1
Chunk 5
---
 — 833 — Total operating costs and expenses39,183 60,631 120,732 88,621 Operating income (loss)8,444 (19,100)(27,772)(16,112)Non-operating income and expenses:   Gain (loss) from short-term investments939 (14,256)(11,428)96,516    Interest income1,621 2,757 3,392 4,777    Interest expense(1,153)(1,268)(2,020)(1,411)   Other non-operating expense, net1,372 (33,523)(1,129)(35,713)Total non-operating income (expenses), net2,779 (46,290)(11,185)64,169 Income (loss) before income taxes11,223 (65,390)(38,957)48,057 Income tax (expense) benefit (6,376)13,479 1,353 (13,829)Net income (loss)$4,847 $(51,911)$(37,604)$34,228      Basic net income (loss) per share$0.25 $(2.88)$(1.95)$1.91      Shares used in basic per share calculation19,327 18,028 19,259 17,880      Diluted net income (loss) per share$0.24 $(2.88)$(1.95)$1.87      Shares used in diluted per share calculation19,926 18,028 19,259 18,282 

See accompanying notes to unaudited condensed consolidated financial statements.

5

LIGAND PHARMACEUTICALS INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME 

(Unaudited)

(in thousands)

Three months endedSix months ended June 30,June 30,2025202420252024Net income (loss) $4,847 $(51,911)$(37,604)$34,228 Unrealized net loss on available-for-sale securities, net of tax(49)(25)(71)(118)Foreign currency translation adjustment, net of tax10,106 — 14,507 — Comprehensive income (loss)$14,904 $(51,936)